Uveal Melanoma Therapeutics Market: By Disease Type, By Treatment Type, By Distribution Channel, and Region Forecast 2020-2031
Uveal Melanoma Therapeutics Market size was valued at US$ 1.35 billion in 2024 and is expected to reach US$ 1.98 billion by 2031, at a CAGR of 5.6% from 2025 to 2031. Uveal melanoma is a disease in which malignant (cancer) cells form in the tissues of the eye. The tumors arise from the melanocytes that reside within the uvea giving color to the eye. Uveal melanoma begins between the three layers of the wall of the eye. The first layer (outer layer) includes sclera and the cornea at the front of the eye. The inner layer has a retina, that senses light and send images. The middle layer is the layer in which the melanoma forms. This layer is called as uvea. Bristol-Myers Squibb and National Cancer Institute (NCI) completed the phase II study of Nivolumab in combination with Ipilimumab for Uveal Melanoma.
Study Period
2025-2031Base Year
2024CAGR
5.6%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
Increase in the prevalence of uveal melanoma is driving the growth of the market. The rising awareness among the people regarding the disease among healthcare fraternity is anticipated to drive the growth of the uveal melanoma therapeutics market. However, the higher cost of the therapy and reimbursement policies are may constrain the growth of the market.
The market is driven by increase in the prevalence of the eye related disorders. The growing patient population with uveal melanoma disorder expected fuel the market growth in the region. According to the American Cancer Society, about nine of 10 melanomas of the eye develop in the choroid. It also states that 2,730 new cases were detected in 2014 of uveal melanoma in the U.S.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 1.35 billion |
|
Market Size in 2031 |
US$ 1.98 billion |
|
Market CAGR |
5.6% |
|
By Disease Type |
|
|
By Choroidal Melanomas |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The global uveal melanoma therapeutics market size was valued at US$ 1.35 billion in 2024 and growing at a CAGR of 5.6% from 2025 to 2031.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The uveal melanoma therapeutics market key players are Eli Lilly & Co. (U.S), Novartis AG (Switzerland), AstraZeneca plc (UK), Pfizer, Inc. (U.S), Merck (U.S), Roche (Switzerland), Amgen (U.S), Bayer (Germany), Spectrum Pharmaceuticals, Inc. (U.S)
| 1. Executive Summary |
| 2. Global Uveal Melanoma Therapeutics Market Introduction |
| 2.1. Global Uveal Melanoma Therapeutics Market - Taxonomy |
| 2.2. Global Uveal Melanoma Therapeutics Market - Definitions |
| 2.2.1. By Disease Type |
| 2.2.2. By Choroidal Melanomas |
| 2.2.3. By Distribution Channel |
| 2.2.4. By Region |
| 3. Global Uveal Melanoma Therapeutics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Key Developments |
| 4. Global Uveal Melanoma Therapeutics Market By Disease Type, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 4.1. Choroidal Melanomas |
| 4.1.1. Small Melanomas |
| 4.1.1.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 4.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.1.3. Market Opportunity Analysis |
| 4.1.2. Medium-sized Melanomas |
| 4.1.2.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 4.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.2.3. Market Opportunity Analysis |
| 4.1.3. Large Melanomas |
| 4.1.3.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 4.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.3.3. Market Opportunity Analysis |
| 4.2. Iris melanomas |
| 4.2.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.2.3. Market Opportunity Analysis |
| 4.3. Ciliary Body Melanomas |
| 4.3.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.3.3. Market Opportunity Analysis |
| 5. Global Uveal Melanoma Therapeutics Market By Choroidal Melanomas, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 5.1. Chemotherapy |
| 5.1.1. Methotrexate |
| 5.1.1.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 5.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.1.3. Market Opportunity Analysis |
| 5.1.2. Others |
| 5.1.2.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 5.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.2.3. Market Opportunity Analysis |
| 5.2. Immunotherapy Drugs |
| 5.2.1. Pembrolizumab |
| 5.2.1.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 5.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.1.3. Market Opportunity Analysis |
| 5.2.2. Ipilimumab |
| 5.2.2.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 5.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.2.3. Market Opportunity Analysis |
| 5.2.3. Others |
| 5.2.3.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 5.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3.3. Market Opportunity Analysis |
| 5.3. Targeted Drugs |
| 5.3.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Uveal Melanoma Therapeutics Market By Distribution Channel, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 6.1. Hospital Pharmacies |
| 6.1.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Retail Pharmacies |
| 6.2.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Online Pharmacies |
| 6.3.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Uveal Melanoma Therapeutics Market By Region, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific |
| 7.3.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. MEA |
| 7.5.1. Market Analysis, 2019-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8. North America Uveal Melanoma Therapeutics Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 8.1. Disease Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Choroidal Melanomas |
| 8.1.1.1. Small Melanomas |
| 8.1.1.2. Medium-sized Melanomas |
| 8.1.1.3. Large Melanomas |
| 8.1.2. Iris melanomas |
| 8.1.3. Ciliary Body Melanomas |
| 8.2. Choroidal Melanomas Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Chemotherapy |
| 8.2.1.1. Methotrexate |
| 8.2.1.2. Others |
| 8.2.2. Immunotherapy Drugs |
| 8.2.2.1. Pembrolizumab |
| 8.2.2.2. Ipilimumab |
| 8.2.2.3. Others |
| 8.2.3. Targeted Drugs |
| 8.3. Distribution Channel Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1. Hospital Pharmacies |
| 8.3.2. Retail Pharmacies |
| 8.3.3. Online Pharmacies |
| 8.4. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.4.1. USA |
| 8.4.2. Canada |
| 9. Europe Uveal Melanoma Therapeutics Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 9.1. Disease Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Choroidal Melanomas |
| 9.1.1.1. Small Melanomas |
| 9.1.1.2. Medium-sized Melanomas |
| 9.1.1.3. Large Melanomas |
| 9.1.2. Iris melanomas |
| 9.1.3. Ciliary Body Melanomas |
| 9.2. Choroidal Melanomas Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Chemotherapy |
| 9.2.1.1. Methotrexate |
| 9.2.1.2. Others |
| 9.2.2. Immunotherapy Drugs |
| 9.2.2.1. Pembrolizumab |
| 9.2.2.2. Ipilimumab |
| 9.2.2.3. Others |
| 9.2.3. Targeted Drugs |
| 9.3. Distribution Channel Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. Hospital Pharmacies |
| 9.3.2. Retail Pharmacies |
| 9.3.3. Online Pharmacies |
| 9.4. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1. Germany |
| 9.4.2. France |
| 9.4.3. Italy |
| 9.4.4. Spain |
| 9.4.5. UK |
| 9.4.6. Rest of Europe |
| 10. Asia Pacific Uveal Melanoma Therapeutics Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 10.1. Disease Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Choroidal Melanomas |
| 10.1.1.1. Small Melanomas |
| 10.1.1.2. Medium-sized Melanomas |
| 10.1.1.3. Large Melanomas |
| 10.1.2. Iris melanomas |
| 10.1.3. Ciliary Body Melanomas |
| 10.2. Choroidal Melanomas Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Chemotherapy |
| 10.2.1.1. Methotrexate |
| 10.2.1.2. Others |
| 10.2.2. Immunotherapy Drugs |
| 10.2.2.1. Pembrolizumab |
| 10.2.2.2. Ipilimumab |
| 10.2.2.3. Others |
| 10.2.3. Targeted Drugs |
| 10.3. Distribution Channel Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Hospital Pharmacies |
| 10.3.2. Retail Pharmacies |
| 10.3.3. Online Pharmacies |
| 10.4. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1. China |
| 10.4.2. Japan |
| 10.4.3. South Korea |
| 10.4.4. India |
| 10.4.5. Rest of APAC |
| 11. Latin America Uveal Melanoma Therapeutics Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 11.1. Disease Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Choroidal Melanomas |
| 11.1.1.1. Small Melanomas |
| 11.1.1.2. Medium-sized Melanomas |
| 11.1.1.3. Large Melanomas |
| 11.1.2. Iris melanomas |
| 11.1.3. Ciliary Body Melanomas |
| 11.2. Choroidal Melanomas Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Chemotherapy |
| 11.2.1.1. Methotrexate |
| 11.2.1.2. Others |
| 11.2.2. Immunotherapy Drugs |
| 11.2.2.1. Pembrolizumab |
| 11.2.2.2. Ipilimumab |
| 11.2.2.3. Others |
| 11.2.3. Targeted Drugs |
| 11.3. Distribution Channel Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. Hospital Pharmacies |
| 11.3.2. Retail Pharmacies |
| 11.3.3. Online Pharmacies |
| 11.4. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1. Brazil |
| 11.4.2. Mexico |
| 11.4.3. Argentina |
| 11.4.4. Rest of Latin America |
| 12. MEA Uveal Melanoma Therapeutics Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 12.1. Disease Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Choroidal Melanomas |
| 12.1.1.1. Small Melanomas |
| 12.1.1.2. Medium-sized Melanomas |
| 12.1.1.3. Large Melanomas |
| 12.1.2. Iris melanomas |
| 12.1.3. Ciliary Body Melanomas |
| 12.2. Choroidal Melanomas Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Chemotherapy |
| 12.2.1.1. Methotrexate |
| 12.2.1.2. Others |
| 12.2.2. Immunotherapy Drugs |
| 12.2.2.1. Pembrolizumab |
| 12.2.2.2. Ipilimumab |
| 12.2.2.3. Others |
| 12.2.3. Targeted Drugs |
| 12.3. Distribution Channel Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. Hospital Pharmacies |
| 12.3.2. Retail Pharmacies |
| 12.3.3. Online Pharmacies |
| 12.4. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1. GCC Countries |
| 12.4.2. South Africa |
| 12.4.3. Rest of MEA |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Eli Lilly & Co. (U.S) |
| 13.2.2. Novartis AG (Switzerland) |
| 13.2.3. AstraZeneca plc (UK) |
| 13.2.4. Pfizer, Inc. (U.S) |
| 13.2.5. Merck (U.S) |
| 13.2.6. Roche (Switzerland) |
| 13.2.7. Amgen (U.S) |
| 13.2.8. Bayer (Germany) |
| 13.2.9. Spectrum Pharmaceuticals, Inc. (U.S) |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
